The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell Lymphoma
Abstract
Purpose: To discuss vorinostat approval for treatment of cutaneous manifestations of advanced cutaneous T-cell lymphoma (CTCL). Experimental Design: Data from 1 single-arm, open-label, multicenter pivotal trial and 11 other trials submitted to support the new drug application for vorinostat in the treatment of advanced primary CTCL were reviewed. The pivotal trial assessed responses by changes in overall skin disease score using a severity-weighted assessment tool (SWAT). Vorinostat could be considered active in CTCL if observed response rate was at least 20% and the lower bound of the corresponding 95% confidence interval (95% CI) excluded 5%. Patients reported pruritis relief using a questionnaire and a visual analogue scale. Results: The pivotal trial enrolled 74 patients with stage IB or higher CTCL. Median number of prior treatments was 3, and 61 patients (82%) had stage IIB or higher disease. The objective response rate in the skin disease assessed by change in the overall SWAT score from the baseline was 30% (95% CI, 18.5 to 42.6) in patients with stage IIB or higher disease. Median response duration (end of response defined by 50% increase in SWAT score from the nadir) was 168 days. Median time to tumor progression was 148 days for overall population and 169 days for patients with stage IIB or higher disease. Assessment of pruritis relief was considered unreliable. Conclusions: Vorinostat showed activity in CTCL, and skin responses were a clinical benefit. Vorinostat was approved for treatment of cutaneous manifestations of CTCL. A nonblinded, single-arm trial did not allow a reliable assessment of pruritis relief.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome
Trautinger, F., Knobler, R., Willemze, R., Peris, K., Stadler, R., Laroche, L., D’Incan, M., Ranki, A., Pimpinelli, N., Ortiz-Romero, P., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.025 · Cited by 416
Primary Cutaneous T-Cell Lymphoma: Review and Current Concepts
Siegel, R. S., Pandolfino, T., Guitart, J., Rosen, S., & Kuzel, T. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.15.2908 · Cited by 308
Whittaker, S. J., Marsden, J. R., Spittle, M., & Russell Jones, R. (2003) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2003.05698.x · Cited by 241
Rubin, E. H., Agrawal, N. G. B., Friedman, E. J., Scott, P., Mazina, K. E., Sun, L., Du, L., Ricker, J. L., Frankel, S. R., Gottesdiener, K. M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1802 · Cited by 115
American Joint Committee on Cancer (2002) · Springer eBooks · doi:10.1007/978-1-4757-3656-4_48 · Cited by 9
Cited by
Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target
Infantino, V., Santarsiero, A., Convertini, P., Todisco, S., & Iacobazzi, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115703 · Cited by 499
Lim, S., Janzer, A., Becker, A., Zimmer, A., Schüle, R., Buettner, R., & Kirfel, J. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp324 · Cited by 470
Vizioli, M. G., Liu, T., Miller, K. N., Robertson, N. A., Gilroy, K., Lagnado, A. B., Perez-Garcia, A., Kiourtis, C., Dasgupta, N., Lei, X., et al. (2020) · Genes & Development · doi:10.1101/gad.331272.119 · Cited by 359
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
HIF Inhibitors: Status of Current Clinical Development
Fallah, J., & Rini, B. I. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0752-z · Cited by 308
Metadata
- Authors
- Mann, B. S., Johnson, J. R., He, K., Sridhara, R., Abraham, S., Booth, B. P., Verbois, L., Morse, D. E., Jee, J. M., Pope, S., Harapanhalli, R. S., Dagher, R., Farrell, A., Justice, R., & Pazdur, R.
- Venue
- Clinical Cancer Research
- Published
- 2007-04-15
- Volume
- 13
- Issue
- 8
- Pages
- 2318-2322
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2102169774
- Cited by
- 262
- References
- 6
- FWCI
- 19.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell Lymphoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-06-2672
- The paper
- Mann, B. S., Johnson, J. R., He, K., Sridhara, R., Abraham, S., Booth, B. P., Verbois, L., Morse, D. E., Jee, J. M., Pope, S., Harapanhalli, R. S., Dagher, R., Farrell, A., Justice, R., & Pazdur, R. (2007). Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell Lymphoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-06-2672
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.